

# Simona Coco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4931458/publications.pdf>

Version: 2024-02-01

102  
papers

2,756  
citations

201674

27  
h-index

197818

49  
g-index

103  
all docs

103  
docs citations

103  
times ranked

5533  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
2	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	4.4	103
3	Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma. <i>BMC Cancer</i> , 2009, 9, 441.	2.6	95
4	Exosomes: a new horizon in lung cancer. <i>Drug Discovery Today</i> , 2017, 22, 927-936.	6.4	90
5	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2020, 12, 17.	3.7	82
6	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 799455.	4.8	76
7	Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. <i>Cancer</i> , 2008, 113, 1412-1422.	4.1	65
8	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. <i>Frontiers in Oncology</i> , 2014, 4, 242.	2.8	63
9	Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , 2021, 81, 724-731.	0.9	57
10	Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1591-1600.	5.1	53
11	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 125.	4.8	53
12	High Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma. <i>Neoplasia</i> , 2012, 14, 823-IN10.	5.3	48
13	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017, 22, 1266-1273.	6.4	48
14	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	2.4	45
15	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: <sup>18</sup> F-FDG PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1764-1769.	5.0	44
16	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	3.7	43
17	Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 20-29.	1.0	39
18	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1035.	4.1	39

#	ARTICLE	IF	CITATIONS
19	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. <i>Current Drug Targets</i> , 2015, 16, 47-59.	2.1	38
20	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	4.1	38
21	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. <i>Journal of Pathology</i> , 2005, 207, 346-357.	4.5	36
22	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM <sup>®</sup> Platform. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28765-28782.	4.1	35
23	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. <i>Targeted Oncology</i> , 2015, 10, 393-404.	3.6	34
24	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. <i>Drug Discovery Today</i> , 2014, 19, 1671-1676.	6.4	33
25	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2865-2878.	5.4	31
26	Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors. <i>Molecular Cancer Research</i> , 2011, 9, 815-823.	3.4	29
27	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. <i>BMC Cancer</i> , 2016, 16, 692.	2.6	27
28	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2055-2062.	1.8	27
29	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 68627-68640.	1.8	27
30	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	2.4	26
31	Familial neuroblastoma: a complex heritable disease. <i>Cancer Letters</i> , 2003, 197, 41-45.	7.2	24
32	Genomic aberrations in normal appearing mucosa fields distal from oral potentially malignant lesions. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 43-52.	4.4	24
33	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	1.8	24
34	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	1.8	24
35	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	4.2	24
36	Chromosomal aberrations and aneuploidy in oral potentially malignant lesions: distinctive features for tongue. <i>BMC Cancer</i> , 2011, 11, 445.	2.6	23

#	ARTICLE	IF	CITATIONS
37	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	2.4	23
38	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1585-1599.	1.8	22
39	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019, 25, 15.	4.4	22
40	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 889-903.	1.8	21
41	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 513-523.	4.1	21
42	Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. <i>Journal of Human Genetics</i> , 2012, 57, 682-684.	2.3	19
43	Epigenetic Silencing of DKK3 in Medulloblastoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 7492-7505.	4.1	18
44	Gene expression profiling identifies eleven DNA repair genes down-regulated during mouse neural crest cell migration. <i>International Journal of Developmental Biology</i> , 2011, 55, 65-72.	0.6	15
45	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	2.5	15
46	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016, 5, 12-18.	1.2	15
47	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	3.3	15
48	Belagenpumatucel-L for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1371-1379.	3.1	12
49	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. <i>Medicine (United States)</i> , 2016, 95, e5447.	1.0	12
50	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e50-e52.	1.1	11
51	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2015, 137, 2947-2958.	5.1	11
52	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 125.	3.7	11
53	Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies. <i>Current Pharmaceutical Design</i> , 2009, 15, 448-455.	1.9	10
54	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1007-1017.	3.1	10

#	ARTICLE	IF	CITATIONS
55	Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm. <i>BMC Medical Genomics</i> , 2015, 8, 57.	1.5	10
56	Transcribed-ultra conserved region expression profiling from low-input total RNA. <i>BMC Genomics</i> , 2010, 11, 149.	2.8	9
57	Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments. <i>Journal of Personalized Medicine</i> , 2021, 11, 182.	2.5	9
58	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1142-1154.	1.7	8
59	Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 423-426.	1.5	7
60	Chromosome 9q and 16q Loss Identified by Genome-Wide Pooled-Analysis Are Associated with Tumor Aggressiveness in Patients with Classic Medulloblastoma. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 273-280.	2.0	7
61	Performance of the OncoPrint™ Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2895.	2.5	7
62	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	1.8	6
63	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	1.5	5
64	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 551-561.	4.1	5
65	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	3.4	5
66	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	1.3	4
67	Aquatic reservoir of <i>Vibrio cholerae</i> in an African Great Lake assessed by large scale plankton sampling and ultrasensitive molecular methods. <i>ISME Communications</i> , 2021, 1, .	4.2	4
68	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e637-e641.	2.6	4
69	MicroRNA Alterations Induced in Human Skin by Diesel Fumes, Ozone, and UV Radiation. <i>Journal of Personalized Medicine</i> , 2022, 12, 176.	2.5	4
70	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	4.1	4
71	NSD1 Mutations in Sotos Syndrome Induce Differential Expression of Long Noncoding RNAs, miR646 and Genes Controlling the G2/M Checkpoint. <i>Life</i> , 2022, 12, 988.	2.4	4
72	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 3412.	3.7	4

#	ARTICLE	IF	CITATIONS
73	Loss of 10q26.1â€“q26.3 in association with 7q34â€“q36.3 gain or 17q24.3â€“q25.3 gain predict poor outcome in pediatric medulloblastoma. <i>Cancer Letters</i> , 2011, 308, 215-224.	7.2	3
74	Vinflunine for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1447-1455.	4.1	3
75	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S827-S828.	1.1	3
76	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. <i>Cancers</i> , 2019, 11, 441.	3.7	3
77	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	1.8	3
78	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	2.4	3
79	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	2.0	3
80	P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, S829-S830.	1.1	2
81	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 21, 218-230.e6.	2.4	2
82	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, S825-S826.	1.2	2
83	Identification by MicroRNA Analysis of Environmental Risk Factors Bearing Pathogenic Relevance in Non-Smoker Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 666.	2.5	2
84	3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, S644.	2.8	1
85	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1357-1364.	0.8	1
86	Reply to the Letter to the Editor by C. Nicolazzo et al.: â€œCirculating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapyâ€• <i>International Journal of Molecular Sciences</i> , 2017, 18, 1309.	4.1	1
87	Abstract 1424: KCNJ2 comprises a marker of poor prognosis and a therapeutic target in non-WNT/non-SHH medulloblastoma. , 2012, , .		1
88	MicroRNA prognostic signature in malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7562-7562.	1.6	1
89	Oligonucleotide Array Comparative Genomic Hybridization Profiling of Neuroblastoma Tumours. <i>Cancer Genomics and Proteomics</i> , 2006, 3, 245-252.	2.0	1
90	A Novel Prognostic Microrna Signature in Malignant Pleural Mesothelioma. <i>Annals of Oncology</i> , 2014, 25, iv542.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	1.8	0
92	Clinical applications of a next-generation sequencing panel in non-small cell lung cancer. Annals of Oncology, 2015, 26, vi87.	1.2	0
93	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S730-S731.	1.1	0
94	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. Journal of Thoracic Oncology, 2018, 13, S726-S727.	1.1	0
95	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. Annals of Oncology, 2018, 29, viii674.	1.2	0
96	P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patientsâ€™ Stratification and Identification of Responders to Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S458.	1.1	0
97	1216P A circulating exosomal miRNA-based risk score as a predictive biomarker of relapse in early stage non-small cell lung cancer. Annals of Oncology, 2020, 31, S795.	1.2	0
98	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. Journal of Clinical Oncology, 2021, 39, e21007-e21007.	1.6	0
99	Abstract 5649: Investigational study of acquired resistance to the EGFR irreversible inhibitor afatinib (BIBW2992) in wild-type and EGFR-mutant NSCLC cell lines.. , 2013, , .		0
100	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).. Journal of Clinical Oncology, 2015, 33, e19090-e19090.	1.6	0
101	Abstract 4008: MiRNA expression profiling reveals a prognostic signature in malignant pleural mesothelioma. , 2015, , .		0
102	Abstract 2521: In vitro and in vivo antitumor efficacy of sequentially combined vinorelbine and gefitinib in non-small cell lung cancer. , 2015, , .		0